STOCK TITAN
  1. Home
  2. MACK

Merrimack Pharmaceuticals (MACK) Stock Price, News & Analysis

MACK NASDAQ
Published by Stock Titan Data refreshed

What Changed

Price Move History

Daily moves over 5%
1 253 sessions, May 24, 2023 to May 24, 2024
Largest daily move
+7.2% close of February 13, 2024
1-year change
+21.3% closing prices, May 24, 2023 to May 24, 2024
1-month change
+2.9% closing prices, April 24, 2024 to May 24, 2024

Company Description

Merrimack Pharmaceuticals (NASDAQ: MACK) is classified in the pharmaceutical preparations industry.

MACK gained 21.3% in the 12 months to May 24, 2024. The last closing price was $15.13.

This page collects what Stock Titan holds for MACK, including price data and latest news.

Stock Performance

Chart
$15.13
No recent trading
Last close: May 24, 2024
+21.3%
1 year to May 24, 2024
-
Market Cap
14.8M
Shares outstanding

Merrimack Pharmaceuticals (MACK) closed at $15.13 on May 24, 2024. In the 12 months to May 24, 2024, the price gained 21.3%.

See what a $1,000 investment in MACK would be worth today

Average down calculator for MACK

MACK Metrics & Rankings

May 2024
+2.6%
—
2024
+12.8%
—

Price returns through May 24, 2024. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

View All
-0.13%

Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock

dividends
+0.27%

Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution

dividends
+1.63%

Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution

+0.14%

Merrimack Receives $225 Million Milestone Payment from Ipsen

-0.34%

Merrimack Reports Full Year 2023 Financial Results

earnings
-2.20%

Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

fda approval
+1.13%

Merrimack Reports Third Quarter 2023 Financial Results

earnings
+0.17%

Merrimack Reports Second Quarter 2023 Financial Results

earnings
+0.79%

Merrimack Reports First Quarter 2023 Financial Results

earnings
-0.26%

Merrimack Reports Full Year 2022 Financial Results

earnings

Merrimack Pharmaceuticals has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 4 with negative movement. Key topics include dividends, earnings, fda approval. View all MACK news →

SEC Filings

No SEC filings available for MACK.

MACK Company Profile & Sector Positioning

Merrimack Pharmaceuticals (MACK) and is listed on the NASDAQ.

Frequently Asked Questions

Merrimack Pharmaceuticals (MACK) has no recent trading. Its last close was $15.13 on May 24, 2024.